Aarti Drugs Ltd (AARTIDRUGS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Aarti Drugs Ltd on NSE and BSE, with an AI summary of each filing.
Audio recording for conference call for Analyst and Investors
Audio / Video · 05 Nov 2026, 12:55 am
Aarti Drugs Releases Q2/H1 FY27 Earnings Conference Call Audio Recording Aarti Drugs Limited has made available the audio recording for its investors and analysts conference call discussing the financial results for the quarter and half-year ended 30th Sep'26. The recording is accessible on the company's official website via its designated concall recordings link. Additionally, the company confirmed that the written transcript of the earnings call will be submitted to the stock exchanges and uploaded to its website in due course.
Investor Presentation for Q2 FY27
Investor Presentation · 04 Nov 2026, 3:17 am
Aarti Drugs Reports Strong Q2 FY27 Earnings Driven by Margin Expansion Aarti Drugs delivered robust Q2 FY27 performance, with total revenue rising 27% YoY to Rs 828.8 crore and net profit jumping 83% YoY to Rs 82.8 crore. EBITDA grew 63% YoY to Rs 137.9 crore, with margins expanding 370 bps YoY to a multi-year high of 16.6%, aided by higher realizations and backward integration at the Sayakha facility. Formulations and Specialty Chemicals drove broad-based growth. Ongoing brownfield expansions across anti-diabetic and anti-inflammatory segments remain on track to deepen penetration in regulated markets.
Press release on Financial results for Quarter and Half year ended September 2026
Press Release · 04 Nov 2026, 2:47 am
Aarti Drugs Reports Strong Q2 FY27 Results with 83% YoY PAT Growth Aarti Drugs reported a solid Q2 FY27 performance, with consolidated revenue rising 27% YoY to Rs. 828.8 crore. EBITDA surged 63% YoY to Rs. 137.9 crore, expanding margins by 370 bps to 16.6%. PAT jumped 83% YoY to Rs. 82.8 crore, driven by strong realisations across API, Formulations (+58% YoY to Rs. 130 crore), and Specialty Chemicals (+92% YoY to Rs. 71.8 crore). In H1 FY27, revenue grew 23% YoY to Rs. 1,532.4 crore, while PAT rose 34% YoY to Rs. 132.9 crore.
Financial Results for the quarter and half year ended September 30, 2026
Outcome · 04 Nov 2026, 12:38 am
Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 12:33 am
Financial Results for the quarter and half year ended September 30, 2026
Financial Result · 04 Nov 2026, 12:33 am
Aarti Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 82,624 (+26.6% YoY | +17.6% QoQ) ■ EBITDA: 13,536 (+60.6% YoY | +37.9% QoQ) ■ EBITDA Margin (%): 16.4 (+347 bps YoY | +241 bps QoQ) ■ PAT: 8,294 (+83.2% YoY | +65.3% QoQ) ■ EPS (INR): 9.07 (+83.2% YoY | +65.2% QoQ)
Q2 H1 FY27 Earning Conference Call Intimation
Intimation · 04 Nov 2026, 11:00 am
Aarti Drugs Schedules Q2 & H1FY27 Earnings Conference Call Aarti Drugs Limited will host its Q2 & H1FY27 earnings conference call for investors and analysts on 4th Nov'26 at 11:00 AM IST to discuss financial performance for the quarter and half year ended 30th Sep'26. The management team, including Joint Managing Director Harshit Savla, Whole-time Director Harit Shah, Managing Director Adhish Patil, and Pinnacle Life Science Managing Director Vishwa Savla, will represent the company. Dial-in access is available across India, the US, the UK, Singapore, and Hong Kong.
AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Audited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Audited Financial Results for the ....
Intimation · 03 Nov 2026, 5:30 am
Aarti Drugs Schedules Board Meeting to Consider Q2FY27 Audited Results Aarti Drugs Limited has scheduled its Board of Directors meeting for 3rd Nov'26 to consider, approve, and take on record the audited financial results for the quarter and half-year ended 30th Sep'26. In accordance with insider trading regulations, the company's trading window remains closed and will reopen 48 hours after the declaration of the financial results.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
Intimation under Regulation 30 of SEBI LODR, 2015 - Crisil ESG Rating
Others (Uncategorized) · 09 Oct 2026, 12:51 am
CRISIL Assigns 'Strong' ESG Rating of 61 to Aarti Drugs Crisil ESG Ratings & Analytic Limited has assigned an Environmental, Social, and Governance (ESG) rating of 'Crisil ESG 61' (Strong) to Aarti Drugs Limited based on FY'26 data. The report, received by the company on 7th Oct'26, was prepared independently by the SEBI-registered Category-1 ESG rating provider using publicly available information without direct engagement from Aarti Drugs.
Details of Authorized Persons under Regulation 30(5) of the SEBI LODR Regulations, 2015
Others (Uncategorized) · 02 Oct 2026, 12:38 am
Aarti Drugs Updates Authorized Key Management Personnel for Materiality Disclosures Pursuant to Regulation 30(5) of SEBI LODR Regulations and following Directorate and Management changes, Aarti Drugs Limited updated its authorized personnel effective 1st Oct'26. Managing Director Adhish P. Patil and Joint Managing Director Harshit M. Savla are authorized to determine event materiality and make stock exchange disclosures. Additionally, Company Secretary and Compliance Officer Rushikesh V. Deole is authorized to execute disclosures to stock exchanges.
Change in Directorate/ Management
Change in Management · 01 Oct 2026, 1:20 am
Aarti Drugs Announces Key Leadership Transition and Management Changes Aarti Drugs Limited announced the early retirement of Prakash M. Patil, who stepped down as Chairman, Managing Director, and CEO effective from the close of business hours on 30th Sep'26. Following shareholder approval at the AGM on 26th Sep'26, Adhish P. Patil has been promoted to Managing Director effective 1st Oct'26, consequently relinquishing his position as Chief Financial Officer on 30th Sep'26 while continuing CFO oversight until a new appointment is finalized.
Change in Directors/ Management
Change in Management · 27 Sept 2026, 2:01 am
Aarti Drugs Approves Key Leadership Changes and Board Re-Appointments Aarti Drugs shareholders approved major leadership appointments at the 41st AGM on 26th Sep'26. Adhish Prakash Patil has been appointed Managing Director effective 1st Oct'26 following the early retirement of Prakash M. Patil. Nilesh Bhalchandra Patil was appointed Whole-time Director effective 26th Sep'26, replacing retiring Uday Moreshwar Patil. Additionally, the re-appointment of Harshit Manilal Savla as Joint Managing Director and Harit Pragji Shah as Whole-time Director for five-year terms from 1st Jun'27 was approved, alongside the re-appointment of three Independent Directors effective 29th Mar'27.
Scrutinizer''s Report and Voting Results of 41st AGM
Annual General Meeting · 27 Sept 2026, 1:55 am
Presentation made to the shareholders at 41st Annual General Meeting
Investor Presentation · 27 Sept 2026, 1:46 am
Proceedings of 41st Annual General Meeting
Annual General Meeting · 27 Sept 2026, 1:43 am
Please find attached BRSR for FY 2025-26
Others (Uncategorized) · 03 Sept 2026, 3:26 am
Aarti Drugs FY26 BRSR: PTSCL Unit Closure and Escalated ESG Capex Aarti Drugs reported FY26 turnover of ₹2,26,038.50 lakhs and net worth of ₹1,40,479.08 lakhs, with exports driving 38% of revenue. A material regulatory event occurred on 9th Sep'25 when the Maharashtra Pollution Control Board mandated the closure of the chlorosulfonation process at the PTSCL unit following an HCl gas leak, halting production of that specific product. The company increased ESG-focused investments, allocating 15% of total capex and 27% of R&D to environmental improvements. Additionally, 10 of its 12 API manufacturing facilities now operate on Zero Liquid Discharge systems.
Please find attached Notice of 41st Annual General Meeting of the Company
Annual General Meeting · 03 Sept 2026, 3:20 am
Please find attached Annual Report for FY 2025-26
Others (Uncategorized) · 03 Sept 2026, 3:09 am
approval of Aarti Drugs Limited Performance Stock Option Plan 2026
Outcome · 27 Aug 2026, 6:16 pm
Aarti Drugs Board Approves Performance Stock Option Plan 2026 The Board of Directors on Aug 27, '26 approved the "Aarti Drugs Limited Performance Stock Option Plan 2026" (PSOP 2026). The plan allows for the creation and grant of up to 8,00,000 performance stock options to eligible employees. Each option is convertible into one equity share with a face value of Rs. 10. The implementation is subject to shareholder approval and complies with SEBI's Share Based Employee Benefits regulations, 2021.
Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/08/2026 ,inter alia, to consider and approve 'Aarti Drugs Limited - Performance ....
Intimation · 25 Aug 2026, 3:18 am
Aarti Drugs to Consider Performance Stock Option Plan Aarti Drugs Limited has scheduled a Board of Directors meeting on 27 Aug'26 to consider and approve the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'. In relation to this, the company's trading window for insiders will remain closed from 25 Aug'26 until 29 Aug'26.
Intimation of Analyst/ Institutional Meet
Intimation · 14 Aug 2026, 9:30 pm
Aarti Drugs Schedules Analyst/Investor Meeting in Mumbai Aarti Drugs Limited (NSE: AARTIDRUGS) has scheduled a 1x1/group meeting with analysts and institutional investors on 20th Aug'26, from 1:00 PM to 6:00 PM in Mumbai. The event is organized by Systematix. Discussions will be based on publicly available information, with no unpublished price-sensitive information (UPSI) intended for disclosure. The schedule is subject to change.
Disclosure under Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 11 Aug 2026, 3:04 am
Aarti Drugs Wins Tax Litigation in Supreme Court On 10 Aug'26, Aarti Drugs announced the Supreme Court has dismissed a Special Leave Petition filed by the GST Department. This ruling upholds a previous High Court order in the company's favour, concluding a dispute over an alleged erroneous IGST refund of Rs. 20.72 crore and an associated penalty of the same amount. The original show cause notice had proposed a total demand of Rs. 230.70 crore for FY18-FY22. This favourable judgment eliminates a significant financial contingency for the company.
Q1FY27 Earning call transcript
Transcript · 08 Aug 2026, 2:05 am